Sarepta Therapeutics (SRPT) leaps on upgrade, NDA nod

Sarepta Therapeutics Inc SRPT shares climbed 51% to $24.73 following the announcement of submission of rolling NDA for Eteplirsen. SunTrust Robinson Humphrey upgraded Sarepta Therapeutics from neutral to buy and raised the price target from $14.00 to $33.00. Share volume was 9.4 million, compared to an all-day average of 918,000